v3.26.1
SHARE CAPITAL (Disclosure of stock option and share-based payment activity) (Details)
 12 Months Ended
Mar. 31, 2026
Share
$ / shares
Mar. 31, 2025
Share
$ / shares
Number [Abstract]    
Number of share options outstanding in share-based payment arrangement at beginning of period 6,123,334  
Exercised (642,834) (1,700,000)
Number of share options outstanding in share-based payment arrangement at end of period 5,606,667 6,123,334
Weighted average exercise price [Abstract]    
Balance, beginning of year | $ / shares $ 2.32  
Balance, end of year | $ / shares $ 2.05 $ 2.32
Stock option and share-based payment activity [Member]    
Number [Abstract]    
Number of share options outstanding in share-based payment arrangement at beginning of period 6,123,334 7,098,334
Granted 1,579,000 2,000,000
Exercised (642,834) (1,700,000)
Expired (1,452,833) (1,275,000)
Number of share options outstanding in share-based payment arrangement at end of period 5,606,667 6,123,334
Weighted average exercise price [Abstract]    
Balance, beginning of year | $ / shares $ 2.32 $ 2.37
Granted | $ / shares 1.06 1.52
Exercised | $ / shares 0.57 0.45
Expired | $ / shares 2.78 3.84
Balance, end of year | $ / shares $ 2.05 $ 2.32
Triera Biosciences Ltd [Member]    
Number [Abstract]    
Number of share options outstanding in share-based payment arrangement at beginning of period 190,000 195,000
Granted 0 5,000
Exercised 0 0
Expired 0 (10,000)
Number of share options outstanding in share-based payment arrangement at end of period 190,000 190,000
Weighted average exercise price [Abstract]    
Balance, beginning of year | $ / shares $ 1 $ 1
Granted | $ / shares 0 1
Exercised | $ / shares 0 0
Expired | $ / shares 0 1
Balance, end of year | $ / shares $ 1 $ 1